LBPS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Šios dienos apimtis	3 914.00
Vidutinė apimtis	11 314.00
Rinkos kapitalizacija	0.00
EPS	$0 ( 2022-03-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.220 (13.33%)

Tūris Koreliacija

Ilgas: 0.32 (neutral)

Trumpas: -0.32 (neutral)

Signal:(22.657) Neutral

4D pharma plc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
UTHR	0.931
GOOD	0.925
ALXO	0.917
HALO	0.917
BEAT	0.917
BCYC	0.916
CBNK	0.915
PSHG	0.914
EAR	0.91
IBRX	0.908

10 Labiausiai neigiamai susiję koreliacijos
DAKT	-0.934
AXON	-0.914
DUOL	-0.912
LMNR	-0.908
DAIO	-0.901
OSPN	-0.901
BWMX	-0.9
ALTR	-0.899
OMAB	-0.897
ANSS	-0.897

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

4D pharma plc Koreliacija - Valiuta/Žaliavos

0.08
( neutral )

0.18
( neutral )

0.00
( neutral )

0.33
( neutral )

-0.29
( neutral )

-0.22
( neutral )

4D pharma plc Finansinės ataskaitos

Annual	2021
Pajamos:	$718 000
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.520

FY	2021
Pajamos:	$718 000
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.520

FY	2020
Pajamos:	$534 000
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.824

FY	2019
Pajamos:	$211 000
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.94

Financial Reports:

No articles found.

4D pharma plc

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.